伊马替尼联合Hyper-CVAD方案治疗Ph染色体阳性急性淋巴细胞白血病的临床观察  

Clinical observation of imatinib combined with Hyper-CVAD in treatment of adults with Philadelphia chromosome positive acute lymphoblastic leukemia

作　　者：王玫玫 朱卫健[1] 李志新 李小亮[1] 龚五星[1] 

机构地区：[1]珠海市人民医院(暨南大学医学院附属珠海医院)血液肿瘤科,广东珠海519000

出　　处：《临床荟萃》2015年第6期633-636,共4页Clinical Focus

摘　　要：目的观察伊马替尼联合环磷酰胺＋长春新碱＋吡柔比星＋地塞米松或甲氨蝶呤＋阿糖胞苷（HyperCVAD）方案治疗Ph染色体阳性急性淋巴细胞白血病（Ph＋-ALL）患者的临床疗效及安全性。方法我院血液科应用伊马替尼联合Hyper-CVAD方案治疗16例Ph＋-ALL患者,治疗方案为伊马替尼联合Hyper-CVAD（A/B方案）序贯治疗,持续8个疗程,伊马替尼维持治疗24个月。结果 16例患者血液学完全缓解率（HCR）为100%,患者1、2、3年总生存率（OS）分别为（87.1±8.6）%、（72.3±11.9）%和（63.3±13.4）%。不良反应主要为Ⅳ度骨髓抑制,非血液学不良反应均为Ⅰ-Ⅱ度。结论伊马替尼联合Hyper-CVAD方案治疗Ph染色体阳性急性淋巴细胞白血病的临床疗效满意,不良反应可以耐受。Objective To report the efficacy and safety of imatinib combined with Hyper-CVAD chemotherapy regimen in the treatment of patients with Philadelphia chromosome positive acute lymphoblastic leukemia（Ph＋ ALL）. Methods A sequential 24-month and 8-cycle treatment of imatinib combined with Hyper-CVAD（A/B program）was administrated in 1 6 Ph＋ ALL patients treated at our hospital.Results In 1 6 cases,the overall response rate was 100%.And the 1-,2-and 3-year overall survival rates were （87.1 ±8.6）%,（72.3 ±1 1.9）% and （63.3 ±13.4）%, respectively.The most common adverse reaction was bone marrow suppression.Conclusion Imatinib combined with Hyper-CVAD regimen can achieve a satisfactory result in the treatment of patients with Philadelphia chromosome positive acute lymphoblastic leukemia,and the toxicity can be tolerable.

关 键 词：白血病 淋巴细胞 急性 费城染色体 伊马替尼 生存率 

分 类 号：R733.1[医药卫生—肿瘤]